ERBB2 and breast carcinoma: Adding trastuzumab to adjuvant chemotherapy did not improve invasive disease-free survival or OS in HER2-negative breast cancer in clinical trials, which showed 1+ or 2+ staining on immunohistochemistry for HER2, which is FISH-negative [10].